Download MendeleyA monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity.
de Campos-Mata, L., Trinite, B., Modrego, A., Tejedor Vaquero, S., Pradenas, E., Pons-Grifols, A., Rodrigo Melero, N., Carlero, D., Marfil, S., Santiago, C., Raich-Regue, D., Bueno-Carrasco, M.T., Tarres-Freixas, F., Abanco, F., Urrea, V., Izquierdo-Useros, N., Riveira-Munoz, E., Ballana, E., Perez, M., Vergara-Alert, J., Segales, J., Carolis, C., Arranz, R., Blanco, J., Magri, G.(2024) Nat Commun 15: 1051-1051
- PubMed: 38316751
- DOI: https://doi.org/10.1038/s41467-024-45171-9
- Primary Citation of Related Structures:
8C89 - PubMed Abstract:
Here we report the characterization of 17T2, a SARS-CoV-2 pan-neutralizing human monoclonal antibody isolated from a COVID-19 convalescent individual infected during the first pandemic wave. 17T2 is a class 1 VH1-58/κ3-20 antibody, derived from a receptor binding domain (RBD)-specific IgA + memory B cell, with a broad neutralizing activity against former and new SARS-CoV-2 variants, including XBB.1.16 and BA.2.86 Omicron subvariants. Consistently, 17T2 demonstrates in vivo prophylactic and therapeutic activity against Omicron BA.1.1 infection in K18-hACE2 mice. Cryo-electron microscopy reconstruction shows that 17T2 binds the BA.1 spike with the RBD in "up" position and blocks the receptor binding motif, as other structurally similar antibodies do, including S2E12. Yet, unlike S2E12, 17T2 retains its neutralizing activity against all variants tested, probably due to a larger RBD contact area. These results highlight the impact of small structural antibody changes on neutralizing performance and identify 17T2 as a potential candidate for future clinical interventions.
Organizational Affiliation:
Translational Clinical Research Program, Hospital del Mar Research Institute (IMIM), Barcelona, Spain.
